Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.58 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.57 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.57 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.57 |
| ▸ | GPR27 | Q9NS67 | 3/20 | 0.55 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111449 | 0.92 | SLC10A2 (0.65) | KCNA5SLC10A2SLC10A1SLC10A6GPR27 | |
| SCHEMBL5120085 | 0.88 | SLC20A2 (0.63) | KCNA5SLC10A2SLC10A1SLC10A6GPR27 | |
| SCHEMBL5126855 | 0.87 | SLC10A6 (0.71) | KCNA5SLC10A2SLC10A1SLC10A6GPR27 | |
| SCHEMBL5126770 | 0.87 | SLC10A6 (0.67) | KCNA5SLC10A2SLC10A1SLC10A6GPR27 | |
| SCHEMBL5117217 | 0.86 | CCR2 (0.59) | KCNA5 | |
| SCHEMBL5125608 | 0.84 | LMNA (0.63) | KCNA5SLC10A2SLC10A1SLC10A6GPR27 | |
| SCHEMBL5119957 | 0.84 | SLC10A6 (0.60) | KCNA5SLC10A2SLC10A1SLC10A6GPR27 | |
| SCHEMBL5125757 | 0.84 | SLC10A6 (0.69) | KCNA5SLC10A2SLC10A1SLC10A6GPR27 | |
| SCHEMBL10249599 | 0.83 | GPR27 (0.66) | KCNA5SLC10A2SLC10A1SLC10A6GPR27 | |
| SCHEMBL5125023 | 0.83 | MEN1 (0.69) | SLC10A2SLC10A1SLC10A6GPR27AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351703-B2 | Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-01 | — | — | US | disclosed |
| EP-1095015-B1 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | AVENTIS PHARMA GMBH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20050080073-A1 | Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-04-14 | — | — | US | disclosed |
| US-6809089-B2 | FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-26 | — | — | US | disclosed |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| US-6548547-B1 | Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080073-A1 | Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1A2 | KCNA5 1853/4885SLC10A2 1391/4885SLC10A1 1242/4885 |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1B2 | KCNA5 1689/4885SLC10A2 1534/4885SLC10A1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.